NVAX:NASDAQ
Novavax Inc
$9.85
arrow_downward
-3.34%(-0.34) 1D
$9.87
arrow_upward
+0.20% (+0.020)bedtimeAfter hours
Closed: Sep 9, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$10.02
High
$10.24
Low
$9.73
Mkt. cap
1.62B
Avg. vol.
4.66M
Volume
0.00
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
Open
$10.02
High
$10.24
Low
$9.73
Mkt. cap
1.62B
Avg. vol.
4.66M
Volume
0.00
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Investing.com
·
7 hours ago
Novavax at cantor healthcare conference: pivot to licensing gains steam
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com